CarolynNancyKrasnerMD

Oncology • Boston, MA

Instructor in Medicine, Massachusetts General Hospital

Join to view full profile

Dr. Krasner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Krasner's full profile

Already have an account?

Office
55 Fruit Street Yaw 9
Gillette Center for Womens Cancer
Boston, MA 02114
Phone+1 617-724-3200

Fax+1 617-726-2894

Education & Training

Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1995 - 1998
University of Vermont College of MedicineClass of 1995

Certifications & Licensure

MA State Medical License 2000 - 2026
ME State Medical License 2022 - 2026
RI State Medical License 2022 - 2026
CT State Medical License 2022 - 2025

Clinical Trials

Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 2
Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin Start of enrollment: 2004 Oct 01
Completed
Phase 2
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod Start of enrollment: 2008 Aug 01
Active, not recruiting
Phase 2
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer Start of enrollment: 2012 Apr 01
Completed
Phase 2
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer Start of enrollment: 2016 Jun 15
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

219 citations
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal ...
Ursula A. Matulonis, Suzanne Berlin, Percy Ivy, Karin Tyburski, Carolyn N. Krasner
Journal of Clinical Oncology. 2009-11-20
65 citations
Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer
Elizabeth Pham, Michael J. Birrer, Scott Eliasof, Edward Graeme Garmey, Douglas Lazarus
Clinical Cancer Research. 2015-02-15
134 citations
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
Panagiotis A. Konstantinopoulos, Weixiu Luo, Joyce F. Liu, Doga Gulhan, Carolyn N. Krasner
Journal of Clinical Oncology. 2019-08-28

Press Mentions

Ovarian Cancer Patient Benefits from New ResearchSeptember 25th, 2020
Cerulean Pharma - 13 January 2016 - PHARMACYJanuary 13th, 2016

Professional Memberships

American Society of Clinical Oncology - ASCO
Member